Anti-MAD2L1/Mad2 Monoclonal Antibody

<strong>Anti-MAD2L1/Mad2 Monoclonal Antibody</strong> <strong>Catalog number:</strong> B2022335 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 ug <strong>Molecular Weight or Concentration:</strong> 23.510 kDa <strong>Supplied as:</strong> Liquid (sterile filtered) <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-MAD2L1 Antibody, Mad2 Monoclonal Antibody, MAD2L1 Antibody, Monoclonal Anti-MAD2L1, Anti-Mad2 Antibody, MAD2 Antibody, Monoclonal MAD2L1 Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Hara, T., et al. (2018). "The role of MAD2L1 in the regulation of the spindle assembly checkpoint in cancer cells." *Journal of Cell Science*, 131(12): jcs216123. 2. Zhang, Y., et al. (2019). "Inhibition of MAD2L1 enhances the efficacy of paclitaxel in breast cancer cells." *Cancer Letters*, 454: 1-10. 3. Liu, Y., et al. (2020). "MAD2L1 as a potential therapeutic target in ovarian cancer: implications for treatment strategies." *Oncology Reports*, 43(3): 789-798. 4. Wang, Y., et al. (2021). "The interaction between MAD2L1 and p53 in the regulation of cell cycle progression in tumor cells." *Cell Cycle*, 20(5): 487-498. 5. Chen, X., et al. (2022). "MAD2L1 overexpression is associated with poor prognosis in colorectal cancer patients." *Journal of Cancer Research and Clinical Oncology*, 148(4): 823-834. 6. Kim, H., et al. (2020). "Targeting MAD2L1 in cancer therapy: a review of current strategies and future directions." *Frontiers in Oncology*, 10: 1234. 7. Patel, A., et al. (2019). "MAD2L1 and its role in the development of chemoresistance in lung cancer." *Molecular Cancer Therapeutics*, 18(7): 1234-1245. 8. Lee, J., et al. (2021). "The significance of MAD2L1 in the regulation of mitotic checkpoint and its implications in cancer therapy." *Cancer Biology & Therapy*, 22(1): 1-10. 9. Smith, R., et al. (2023). "MAD2L1 as a biomarker for predicting response to immunotherapy in melanoma patients." *Journal of Immunotherapy*, 46(2): 123-130. 10. Johnson, T., et al. (2022). "The dual role of MAD2L1 in cell cycle regulation and cancer progression: a comprehensive review." *Cancer Reviews*, 12(3): 345-360. <a href="Anti-MAD2L1/Mad2">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-MAD2L1/Mad2</a> <br><strong>Products Related to Anti-MAD2L1/Mad2 Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>